Idenix Pharmaceuticals Revenue Growth: -30.36%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
None selected
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
IDIX Revenue Growth Rankings
| Overall | 4th percentile | 4221 of 4424 |
| Sector | 10th percentile | 416 of 464 in Healthcare |
| Industry | 21st percentile | 100 of 127 in Biotechnology |
IDIX Revenue Growth Range, Past 5 Years
| Minimum | -62.39% | Jun 2005 |
| Maximum | 1365% | Jun 2004 |
| Average |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these IDIX related companies
IDIX News
@js_thorne $IDIX Alot going on behind the scenes so it CAN only be good going forward is my guess.
about a day ago by GArgondizza
about a day ago by GArgondizza
$IDIX big guys flushing stock and accumulating large positions?? That's my interperprtation of SEC filings
about a day ago by js_thorne
about a day ago by js_thorne
@StockRaker You were smart $IDIX. The table's been set on this one.
about a day ago by taketheplunge
about a day ago by taketheplunge
@GArgondizza @StockRaker you too my man, $idix im in it to win it just like i did with $inhx :)
about 2 days ago by BILLYTHE3RD
about 2 days ago by BILLYTHE3RD
@pjeffry000 @Eowen57 $idix Sorry about that volume, when i plugged in the stock i assumed the bid n ask and volume was all connected.
about 2 days ago by GArgondizza
about 2 days ago by GArgondizza
RT @GArgondizza $IDIX 2.2 million shares AH more then all day? Hmmm, 86k http://stks.co/2MAv
about 2 days ago by Eowen57
about 2 days ago by Eowen57
RT @GArgondizza $IDIX 2.2 million shares AH more then all day? Hmmm >> negative - seeing only 86K AH one of us is wrong
about 2 days ago by StockRaker
about 2 days ago by StockRaker
$IDIX big fish come in at the right time, not after, not before. in my hopeful opinion...
about 2 days ago by littleguy
about 2 days ago by littleguy
Barclays on U.S. Pharma: A New Era for Hep C Therapy - Starts Coverage on GILD & IDIX
Feb 10, 2:30PM Street Insider
Feb 10, 2:30PM Street Insider
Notable Analyst Rating Changes 02/10: (COP) (JDSU) (ATVI) Upgraded; (ORLY) (XCO) (AKS) Downgraded
Feb 10, 11:17AM Street Insider
Feb 10, 11:17AM Street Insider
A Forward Look, the Year Ahead - Featured Research on Inhibitex, Inc. and Idenix Pharmaceuticals, Inc.
Feb 07, 9:00AM Marketwire
Feb 07, 9:00AM Marketwire
Idenix (IDIX) announces removal of partial clinical hold on HCV nucleotide inhibitor, IDX184
Feb 03, 8:04AM Street Insider
Feb 03, 8:04AM Street Insider
Idenix Announces Removal of the Partial Clinical Hold on HCV Nucleotide Inhibitor, IDX184
Feb 03, 8:04AM Benzinga
Feb 03, 8:04AM Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IDIX | 10.92 | -0.21 | -1.89% | 1.05B |
| ITRI | 41.45 | -0.96 | -2.28% | 1.69B |
| ICGE | 9.85 | -0.15 | -1.50% | 364.15M |
| DUK | 21.48 | 0.02 | 0.09% | 28.60B |
| FALC | 2.77 | -0.08 | -2.81% | 129.39M |
| PTEK | 0.62 | -0.01 | -0.90% | 4.30M |
| IMAX | 21.22 | -0.38 | -1.76% | 1.37B |
| PRGO | 93.31 | -0.74 | -0.79% | 8.70B |
| AAP | 79.99 | -0.13 | -0.16% | 6.13B |
| LOPE | 17.71 | 0.24 | 1.37% | 784.38M |
